A key House committee is calling on Food and Drug Administration (FDA) to “continue and increase” enforcement against CBD companies that make unsanctioned claims about the benefits benefits of cannabidiol as the agency works with Congress to develop a regulatory pathway for the product.
The panel separately noted the U.S. Department of Veterans Affairs’s (VA) efforts to improve education around home loan benefit protections for military veterans who work in state-legal marijuana markets.
Those issues are addressed in new reports attached to annual spending legislation approved by the House Appropriations Committee last week. The bill itself to fund the U.S. Department of Agriculture (USDA), meanwhile, again codifies protections for state hemp programs.
As the 2024 fiscal year appropriations season gets underway, these are some of the first examples of how lawmakers are approaching cannabis policy through that process under Republican control of the House this Congress.
The CBD language in the spending bill report for USDA and FDA says that appropriators are “concerned about the proliferation of foods and dietary supplements marketed in violation of the [federal Food Drug, and Cosmetic Act], including products containing derivatives of the cannabis plant.”
Non-compliant CBD products “pose potential health and safety risks to
Read full article on Marijuana Moment
